FSD Pharma To Buy Canadian Psychedelic Pharmaceutical Firm

  • FSD Pharma Inc HUGE shares rebounded after falling in premarket on acquiring a Canada-based psychedelic pharmaceutical company.
  • Related: See Why FSD Pharma Terminated COVID-19 Trial
  • FSD Pharma has agreed to acquire Lucid Psycheceuticals Inc for approximately $9 million (C$11.3 million) in FSD Pharma stock.
  • Lucid's candidates primarily focus on treating neurodegenerative diseases. Founded in 2020, Lucid has exclusive worldwide licensing rights to a family of new chemical entities from which Lucid-21-302 has been derived. 
  • In addition, Lucid's pipeline includes Lucid-201, a psychedelic drug candidate targeting mental health disorders, and it is also investigating certain cannabinoids.
  • FSD Pharma will issue approximately 4.5 million Class B subordinate voting shares.
  • Price Action: HUGE shares are up 6.40% at $1.83 during the market session on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechLong IdeasM&ANewsPenny StocksHealth CareMoversTrading IdeasGeneralBriefsNeurodegenerative DisorderneurosciencePsychedelics
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!